Literature DB >> 3902265

Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid.

M B Lilly, G A Omura.   

Abstract

Serum methotrexate (MTX) levels were measured in 20 patients who received an oral, intermediate-dose MTX regimen preceded by an IV loading dose, with or without probenecid. Plateau serum MTX levels were relatively modest (less than or equal to 2 X 10(-6)M) during the 24 h of treatment. Pretreatment with probenecid (PBC) led to a doubling of the serum MTX level and a significant increase in the area under the concentration-time curve. Nevertheless, oral therapy is not a suitable means of producing sustained, high (10(-5) molar) MTX levels, even with the addition of PBC.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3902265     DOI： 10.1007/bf00263889

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  Effect of route of administration and effusions on methotrexate pharmacokinetics.

Authors:  S H Wan; D H Huffman; D L Azarnoff; R Stephens; B Hoogstraten
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

2.  The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts.

Authors:  I D Goldman
Journal:  Mol Pharmacol       Date:  1974-03       Impact factor: 4.436

3.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

4.  The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle.

Authors:  V J Harvey; M L Slevin; R C Woollard; A Johnston; M J Barnett; P F Wrigley; P Turner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport.

Authors:  F M Sirotnak; D M Moccio; C H Hancock; C W Young
Journal:  Cancer Res       Date:  1981-10       Impact factor: 12.701

6.  Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux.

Authors:  F M Sirotnak; D M Moccio; C W Young
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

7.  Competitive protein binding assay for methotrexate.

Authors:  C E Myers; M E Lippman; H M Elliot; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

8.  Augmentation of the intracellular levels of polyglutamyl derivatives of methotrexate by vincristine and probenecid in Ehrlich ascites tumor cells.

Authors:  D W Fry; J C Yalowich; I D Goldman
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

9.  Clinical pharmacology of intermediate-dose oral methotrexate.

Authors:  D K Smith; G A Omura; F Ostroy
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

10.  Prolongation and enhancement of serum methotrexate concentrations by probenecid.

Authors:  G W Aherne; E Piall; V Marks; G Mould; W F White
Journal:  Br Med J       Date:  1978-04-29
View more
  2 in total

Review 1.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 2.  Clinically important drug interactions with disease-modifying antirheumatic drugs.

Authors:  C J Haagsma
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 4.271
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.